65,437 trials
Adenocarcinoma of the Pancreas · Advanced Solid Tumors · Cancer
Primary: Determine if the Treatment of AMG 479 at 12 mg/kg and/or 20 mg/kg in Combination With Gemcitabine Improves Overall Survival as Compared With Placebo in Combination With…
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Pain Score — 5.7 score on a scale
Prader-Willi Syndrome · Obesity
Primary: Microbiome Analysis: Alpha Diversity — 4.89 Shannon index
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Postacute Sequelae of Sars-CoV-2 · Post-Acute COVID-19 Syndrome · Widespread Chronic Pain
Primary: Mean Change in Functional Interference From Pain From Baseline to 4 Weeks (Blinded Phase) — 0.454; 0.198 score on a scale
Lumbar Facet Syndrome
Primary: Numeric Pain Rating Scale (NPRS) — 14; 3 Participants
Cigarette Smoking · Nicotine Dependence
Primary: 7-Day Point Prevalence Abstinence — 30; 44 Participants
AIDS-Related Non-Hodgkin Lymphoma · Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8
Primary: Frequency of Observed Adverse Events (AEs) — 100; 100; 100; 100 percentage of participants
Heart Failure
Primary: Number of Participants With Adverse Events — 111; 78 Participants
Bile Salt Export Pump (BSEP) Transporter · Polysorbate 80
Primary: Area-Under-the-Curve (AUC) of Pravastatin After Metformin — 264.2; 170.5 ng/ml × h — p=0.02
Memory Impairment
Primary: Episodic Memory Improvement — 31.8; 31.3 score on a scale — p=0.531
Traumatic Brain Injury
Primary: dACC BOLD Signal (After Active rTMS Session) — -1.14; -1.27 Percentage of BOLD signal change
Opiate Dependence · Cocaine Dependence
Primary: 11C-UCB-J PET Synaptic Density — 4.01; 4.52; 4.62; 5.09 unitless — p=0.011
Diabetic Nephropathy
Primary: Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104 — 18.2; 29.5 Percentage of Participants
Carcinoid Syndrome
Primary: Percentage of Patients Who Are Satisfied With Their Overall Symptom Control — 37; 58; 22; 5 Participants